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A B S T R A C T
Background
Postherpetic neuralgia (PHN) is a complication of acute herpes zoster, which is emerging as a
preferred clinical trial model for chronic neuropathic pain. Although there are published meta-
analyses of analgesic therapy in PHN, and neuropathic pain in general, the evidence base has
been substantially enhanced by the recent publication of several major trials. Therefore, we
have conducted a systematic review and meta-analysis for both efficacy and adverse events of
analgesic therapy for PHN.
Methods and Findings
We systematically searched databases (MEDLINE 1966–2004, EMBASE 1988–2004, CINAHL
1982–2002, and PubMed [29 October 2004]) for trials of PHN. We also searched references of
retrieved studies and review articles for further trials. We included trials that examined adult
patients with PHN of greater duration than 3 mo, that were blinded, randomised, and had at
least one measure of pain outcome. Dichotomous pain outcome data were extracted for 50%
decrease in baseline pain using a hierarchy of pain/pain-relief measurement tools. Where
available, dichotomous data were also collected for adverse events. Calculated estimates of
efficacy included relative benefit and number needed to treat.
Of 62 studies identified, 35 were randomised controlled trials. Of these, 31 were placebo
controlled and suitable for meta-analysis, from which it was possible to extract dichotomous
efficacy outcome data from 25.
This meta-analysis revealed that there is evidence to support the use of the following orally
administered therapies: tricyclic antidepressants, ‘‘strong’’ opioids, gabapentin, tramadol, and
pregabalin. Topical therapies associated with efficacy were lidocaine 5% patch and capsaicin.
Finally, a single study of spinal intrathecal administration of lidocaine and methyl prednisolone
demonstrated efficacy, although this has yet to be replicated.
Data suggest that the following therapies are not associated with efficacy in PHN: certain
NMDA receptor antagonists (e.g., oral memantine, oral dextromethorphan, intravenous
ketamine), codeine, ibuprofen, lorazepam, certain 5HT1 receptor agonists, and acyclovir.
Topical administration of benzydamine, diclofenac/diethyl ether, and vincristine (iontophoresis)
are similarly not associated with efficacy, nor are intrathecal administration of lidocaine alone or
epidural administration of lidocaine and methylprednisolone, intravenous therapy with
lidocaine, subcutaneous injection of Cronassial, or acupuncture. However, many of the trials
that demonstrated a lack of efficacy represented comparatively low numbers of patient
episodes or were single-dose studies, so it may be appropriate to regard such interventions as
‘‘not yet adequately tested’’ rather than demonstrating ‘‘no evidence of efficacy.’’ Topical
aspirin/diethyl ether has not been adequately tested.
Conclusion
The evidence base supports the oral use of tricyclic antidepressants, certain opioids, and
gabapentinoids in PHN. Topical therapy with lidocaine patches and capsaicin is similarly
supported. Intrathecal administration of methylprednisolone appears to be associated with
high efficacy, but its safety requires further evaluation.
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Introduction
Postherpetic neuralgia (PHN) is a chronic neuropathic pain
syndrome that may complicate recovery from an acute attack
of herpes zoster. Despite advances in antiviral therapy during
acute herpes zoster and the more recent introduction of
vaccination against varicella zoster, PHN continues to be a
signiﬁcant clinical problem, with up to 25% of patients
developing persistent neuropathic pain after acute herpes
zoster reactivation [1]. Acute herpes zoster, and, conse-
quently, PHN, particularly afﬂicts the immunocompromised
and elderly, a fact that has serious implications for health-
care delivery in the context of ageing populations in the
developed world and the worldwide spread of HIV disease.
Left untreated, PHN can become a severe and debilitating
condition affecting all aspects of a patient’s life [2].
The nature of neuropathic pain in PHN is variable; it may
be described as continuous or paroxysmal, evoked or
spontaneous, burning or lancinating, and be associated with
a range of other sensory abnormalities in the skin [3]. This
variability in symptomatology could imply that a variety of
different pain mechanisms may be operating in different
patients with PHN or in the same patient at different points
in time [3,4]. This hypothesis has led to the suggestion that
treatment plans could be optimised for individual patients on
the basis of symptoms or even mechanisms [5]. However, the
current situation is that the existing evidence base for
therapies in PHN is constructed largely from clinical trials
of analgesics that have examined PHN as a single disease
entity. Furthermore, no substantial evidence base exists to
relate speciﬁc sets of symptoms or signs to the efﬁcacy of
speciﬁc drugs, and no simple validated methods exist to
determine which neuropathic pain mechanism(s) may be
operating in a single patient. These factors dictate that
current neuropathic pain treatment paradigms are forced to
focus on PHN as a single disease entity.
No single treatment has been shown to be completely
effective for all sufferers of PHN, and in the practical clinical
scenario combinations of analgesic drugs are usually required
to achieve partial relief of pain. Although there are an
increasingly large number of trials that compare various
analgesics to placebo, very few directly compare single
therapies for which an evidence base exists, or address the
issue of combining treatments [6].
Although published systematic reviews have collated the
evidence base for analgesic therapy in PHN [7–9] and
neuropathic pain in general [10], the evidence base has
fundamentally and substantially altered since the publication
of these reviews, with the appearance of several major studies
[11–21], partly because of the increasing recognition of the
usefulness of PHN as a clinical model of neuropathic pain for
trials. Therefore, we have conducted a systematic review and
meta-analysis of analgesic therapy for PHN, which includes
these more recent trials.
Methods
Inclusion Criteria
The time at which the pain of zoster-associated pain
becomes PHN is debated in the literature. We have used the
deﬁnition of pain persisting for longer than 3 mo after the
crusting of skin lesions following an acute attack of herpes
zoster. Trials were sought that examined adult patients with
zoster-associated pain for greater than 3 mo, were blinded,
randomised, and had at least one clinically relevant measure
of pain outcome. Unpublished, letter, and abstract-only
studies were excluded as were studies on prevention of
PHN and anecdotes. Studies where data for PHN were not
analysed separately from other neuropathic pain syndromes
were also excluded. All randomised controlled trials (RCTs)
identiﬁed up to October 2004 were included.
Identification of Studies
The following databases were searched without language
restrictions: MEDLINE 1966–2004, EMBASE 1988–2004,
CINAHL 1982–2002, and PubMed (29 October 2004). Search
terms used were: ‘‘herpes zoster*,’’ ‘‘postherpetic neuralgia*,’’
‘‘neuralgia*,’’ ‘‘pain*,’’ and ‘‘neuropathic*,’’ in combination
with ‘‘randomised,’’ ‘‘random*,’’ ‘‘randomallocation,’’ ‘‘double-
blind,’’ ‘‘controlled clinical trials,’’ ‘‘trials,’’ and ‘‘study.’’ The
Cochrane Controlled Trial Register and Cochrane Library
(2004) database was searched using similar search terms.
References of retrieved studies and review articles were also
searched for further trials.
Quality Assessment
Identiﬁed studies were independently assessed by at least
two of four authors (KH, TJN, ASCR, and RWJ) in order to
ascertain whether the inclusion criteria for PHN were met.
The trials that met the PHN criteria were then quality scored
by the same authors using the ﬁve point ‘‘Jadad’’ scoring
system [22]. Studies were excluded if they achieved a score of
less than three or if the enrolled study population was ten
patients or less [23]. Disagreement between authors as to
scores was adjudicated by ASCR to reach a consensus.
Data Extraction
The following data were extracted from each study: drug or
treatment examined, number of patients enrolled and
analysed, study design and duration, dosing regimen, out-
come measures used, pain-relief outcomes, minor and major
adverse events, and withdrawals. For crossover studies,
patient episodes were calculated as one episode representing
the result for one patient completing one limb of the
crossover, i.e., one patient who completed both active and
placebo arms of a trial was counted as two patient episodes.
For crossover studies, information was extracted regarding
the provision of washout periods and also as to whether
veriﬁcation of the adequacy of any washout period was
performed (e.g., return of pain intensity to baseline before
second treatment period). Data were extracted by two of the
authors (KH, TJN, or ASCR) independently. For the measure-
ment of treatment efﬁcacy, an outcome was considered
clinically relevant if an improvement of 50% or greater in
pain relief was achieved. Where possible, dichotomous data
were extracted; when dichotomous data were not presented
in the published study, the corresponding authors were
contacted and asked to supply such data if they were still
available. Due to the length of time that had elapsed since
many of the publications, these data were often not available.
Data were extracted for the longest follow-up period
reported in each trial.
Because of the wide variety of outcome measures used
across all of the reviewed papers, a hierarchy of outcome
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measures was implemented in line with the system used by
several previous pain-treatment systematic reviews [8,23,24],
as follows: 1) top two values on a ﬁve-point patient-reported
global scale for pain relief or effectiveness or improvement;
2) top three values on a six-point patient-reported global
scale for pain relief or effectiveness or improvement; 3) top
value on a three-point patient-reported global scale for pain
relief or effectiveness or improvement; 4) top two values on a
four-point patient-reported categorical pain-relief scale;
5) 50% or greater reduction on a visual analogue or 11-point
numerical rating scale for pain intensity.
Where available, dichotomous data were collected on
adverse events. A major adverse effect was deﬁned as an
event that precipitated the withdrawal of the patient from the
study, while an adverse event was considered minor if the
patient continued the treatment and completed the trial.
Some studies reported withdrawals not considered to be
related to the treatment separately. However, this approach
was not consistently the case across the included studies, so
we adopted a conservative approach and included all with-
drawals in the ﬁgures for major harm. Comparator trials
using active controls were excluded from the safety analysis,
in keeping with the system used by Collins et al. [8].
Statistical Methods
A quantitative analysis was carried out on those trials
where dichotomous data were available. Estimates of efﬁcacy
calculated were relative beneﬁt (RB) and number needed to
treat (NNT). The difference between active treatment and
placebo was taken as statistically signiﬁcant when the lower
limit of the 95% conﬁdence interval (CI 95%) for RB was
greater than one. If tests of homogeneity were favourable,
pooling of data was carried out for groups of similar
treatments. A qualitative comment is made on those trials
where no dichotomous data were obtainable.
Safety analysis was carried out on placebo-controlled trials
using relative risk (RR) and number needed to harm (NNH). A
ﬁxed-effects model was used for calculating RB and RR with
95% CIs. A statistically signiﬁcant improvement was noted
when the lower limit of the 95% CI for RB was greater than
one. Where RB or RR was not statistically signiﬁcant, the
method proposed by Altman was used to describe the CI for
NNT or NNH [25]. Number needed to treat to beneﬁt
(NNTB) and number needed to treat to harm (NNTH) are
given, so that if NNT was calculated as ten and the 95% CI
40 to20, then this would be expressed as NNT10 (NNTH 20
to : to NNTB 40). If there were no responders in either the
active or placebo-treated groups, then the RB was undeﬁned
and this situation was dealt with by the method proposed by
Fleiss [26]. When calculating odds ratios, 0.5 was added to
each of the cell frequencies in the 2 3 2 table showing
response by treatment allocation. Although the absolute risks
in the arms may vary between trials and may be affected by
factors such as varying lengths of follow-up, the assumption
was made that the RRs would be similar across trials that
addressed the same question. Where possible, combined
ﬁgures for classes of drugs were calculated based on RR
estimates from each of the trials. Heterogeneity tests were
performed on these trials; a value of p . 0.05 was interpreted
to mean that it was appropriate to combine the RRs from
different trials. Calculations were performed using the
methods proposed by Armitage and Berry [27], programming
being undertaken using Microsoft Excel 2000.
Some trials addressing a particular question will show
treatment beneﬁts that are clearly greater or less than the
typical beneﬁt observed in all the other trials addressing that
question; in this case, there is heterogeneity between the trial
outcomes (i.e., trials with a RR that differs from the overall RR
more than would be expected by chance). The method
proposed by Galbraith was used to identify such atypical trials
[28]. If the treatment beneﬁt is greater, we have described such
trials as ‘‘high’’; if it is less, we have described them as ‘‘low.’’
This review is reported in accordance with the QUOROM
guidelines [29].
Results
After the searches were completed, and obvious review articles,
case and series studies, and anecdotes excluded, 62 articles were
retrieved and independently reviewed by at least two of four of
the authors (KH, TJN, RWJ, and ASCR). Twenty-seven studies
were excluded at this stage (Figure 1). Details of excluded papers
and, therefore, interventions that must be regarded as not having
been adequately tested, are shown in Table 1.
Of 35 trials retained for further analysis, 18 were of a
crossover design and 17 were of a parallel group design
(Table 2). Thirty-one trials were placebo controlled (including
‘‘active’’ placebo). Four trials were comparator studies without
a placebo group and therefore could not be included in the
Table 1. Studies Excluded from the Analysis and Therefore
Intervention Not Adequately Tested
Reference Treatment Primary Reason
for Exclusion
[64] Topical aspirin vs. lidocaine gel PHN criteria not met
[65] Topical aspirin in chloroform PHN criteria unclear
[66] Lidoderm patch PHN criteria not met
[67] Benzydamine cream PHN criteria not met
[12] Gabapentin PHN not reported separately
[68] Lidoderm patch PHN not reported separately
[69] Acyclovir , 10 patients enrolled
[70] Carbamazepine , 10 patients enrolled
[71] i.v. ketamine and i.v. morphine , 10 patients enrolled
[72] i.v. magnesium , 10 patients enrolled
[73] EMLA cream Jadad score , 3
[74] Topical aspirin in chloroform Jadad score , 3
[75] Topical clonidine Jadad score , 3
[76] Amitriptyline and zimelidine Jadad score , 3
[77] Capsaicin Jadad score , 3
[78] Chlorprothixene Jadad score , 3
[79] Clomipramine Jadad score , 3
[80] Iontophoresis with calcium
channel blockers
Jadad score , 3
[81] Tramadol Jadad score , 3
[82] Epidural morphine Jadad score , 3
[83] Carbamazepine and clomipramine Jadad score , 3
[84] Topical aspirin /diethyl ether Jadad score , 3
[85] Iontophoresis of vincristine Jadad score , 3
[86] Lidocaine i.v. and
sympathetic blocks
Jadad score , 3
[87] Topical prostaglandin E-1 Jadad score , 3
[88] ATP infusion Jadad score , 3
[89] TENS and acupuncture Jadad score , 3
DOI: 10.1371/journal.pmed.0020164.t001
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meta-analysis. These trials compared amitriptyline to nortrip-
tyline [30], amitriptyline to maprotiline [31], and intrathecal
steroid to epidural steroid [17] and two doses of levorphanol
[21]. Of the remaining 31 trials, we were able to extract
dichotomous outcome data for efﬁcacy meta-analysis from 25
(Table 3). Qualitative comment has beenmade on the included
studies from which dichotomous data could not be extracted.
Data extracted were for the longest follow-up period
reported in each trial. In the vast majority of trials, this was
only until the end of the treatment period, with the
exception of the intrathecal methylprednisolone studies
[16,17] that reported follow-up periods to 24 wk and 2 y,
and one study that examined amitriptyline and followed ten
‘‘good responders’’ for 2 y [31].
In 14 studies, we could not ﬁnd any reference to intent-to-
treat analysis. In these studies, the percentage of non-
completers varied between 1% and 24%. In seven studies,
all recruited patients completed the study, and an additional
13 studies speciﬁcally indicated that an intent-to-treat
analysis had been performed.
Of the 31 included studies, 18 were a crossover design,
notably those published longer ago (see Table 2). The design
of 14 of these studies included a ‘‘washout’’ period, and ten of
which included data that had the effect of verifying the
adequacy of the washout period (e.g., return to baseline pain
intensity before a treatment period).
Efficacy of Antidepressants
Seven RCTs (297 participants recruited) investigated a
range of tricyclic antidepressants, and six of these were of a
crossover design. Five of these trials had extractable
dichotomous outcome data, four of which compared ami-
triptyline, nortriptyline, or desipramine to placebo (Table 3)
[18,32–34]. One trial used either nortriptyline or desipramine
(the desipramine was used as a ‘‘back-up’’ medication when
either the adverse effects of nortriptyline were intolerable or
the dose could not be increased sufﬁciently). The reason for
this design was that the primary aim of the study was to
evaluate two classes of drug (opioid and tricyclic antidepres-
sants) in general, rather than speciﬁc drugs [18]. These four
trials accounted for 248 patient episodes and showed
signiﬁcant beneﬁt associated with tricyclic antidepressant
therapy, both individual trials and as pooled data (NNT 2.64
[2.1–3.54]) (Table 3). The ﬁfth trial was a direct comparison of
Figure 1. QUOROM Statement Flow Diagram
DOI: 10.1371/journal.pmed.0020164.g001
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Table 2. Studies Included in the Efficacy Analysis
Reference Participants
Recruited (Completed)
Design and Duration of Intervention(s) Intervention
[32] 24 (24 completed) Crossover 3-wk combined titration and treatment phase; 1- to
2-wk washout (no verification of adequacy of washout); 3-wk
combined titration and treatment phase
Amitriptyline started 12.5–25 mg/d, titrated to max 137.5 mg/d,
median 75 mg/d in responders, 50 mg/d in non-responders;
Placebo
[33] 62 (41 completed both
treatment periods;
21 partially completed)
Crossover four comparative treatments; 3-wk titration phase;
3-wk treatment phase; 1-wk washout (reference made to return
to baseline pain intensity before each arm, suggesting washout
was adequate); 3-wk titration phase; 3-wk treatment phase
Amitriptyline12.5–150 mg/d, mean 65 mg/d. (n ¼ 34); Loraze-
pam 0.5–6 mg/d, mean 2.4 mg/d (n ¼ 40); Placebo (n ¼ 25)
[34] 26 (19 completed
both arms)
Crossover 2- 3 6-wk treatment phases; No washout Desipramine 12.5–250 mg titrated over 4 wk; ‘‘Active’’ placebo;
Benztropine 0.5–1 mg
[31] 35 (32 completed
both arms)
Crossover 3-wk titration phase; 2-wk treatment phase; 2-wk
washout (verified by similar pain intensities at start of each
treatment period); 2-wk titration phase; 3-wk treatment phase
Amitriptyline, median dose 100 mg/d; Maprotiline, 100 mg/d;
Both drugs start doses 12.5 or 25 mg, titrated up.
[30] 33 (31 completed) Crossover 3-wk titration phase; 2-wk treatment phase; 2-wk
washout (verified by similar pain intensities at start of each
treatment period); 3-wk titration phase; 2-wk treatment phase
Amitriptyline started 10–20 mg/d, titrated to max 150 mg/d;
Nortriptyline started 10–20 mg/d, titrated to max 160 mg/d
[35] 50 (49 completed) Parallel group 8-wk combined titration and treatment phase Amitriptyline started 12.5 mg titrated to max 200 mg (n ¼ 11);
Amitriptyline þ fluphenazine (n ¼ 12); Fluphenazine started
1 mg titrated to max 3 mg (n ¼ 13); Placebo (n ¼ 13)
[18] 71 (50 completed, two
phases; 44 completed,
three phases)
Crossover 1–9-wk titration phase; 2-wk treatment phase; 2–3-
wk tapering phase; 1-wk washout (verified by similar pain inten-
sities at start of each treatment period); Repeated three times
Nortriptyline 40–140 mg/d, mean 89 mg 13 changed to de-
sipramine, mean 63 mg/d; Morphine 15–225 mg/d, mean
91 mg. 26 changed to methadone, mean 15 mg/d; Placebo
[15] 229 (184 completed) Parallel group 4-wk titration phase; 4-wk treatment phase Gabapentin started 300 mg titrated to max. 3,600 mg (divided
tds). 83% achieved . 2,400 mg/d; Placebo
[11] 334 (272 completed) Parallel group 2-wk titration phase; 5-wk treatment phase Gabapentin 1,800 mg/d (n ¼ 115); Gabapentin 2,400 mg/d
(n ¼ 108); Placebo (n ¼ 111)
[13] 173 (132 completed) Parallel group 1-wk titration phase; 8-wk treatment phase Pregabalin started 150 mg/d, titrated to 300–600 mg/d (de-
pending on creatinine clearance); Placebo
[20] 238 (192 completed) Parallel group 1-wk titration phase; 7-wk fixed dose Pregabalin either 150 mg/d or 300 mg/d; Placebo
[36] 50 (38 completed) Crossover 3-wk titration phase; 1-wk treatment phase; No
washout
Oxycodone modified release; Started 10mg bd; Increased to
max 60 mg/d. Mean dose 45 mg/d Placebo
[37] 19 (19 completed) Crossover 3 3 single treatment session; Minimum 48-hr wash-
out (verified by similar pain intensities at start of each treat-
ment period)
i.v. morphine target dose 0.3 mg/kg, max 25 mg i.v. lido-
caine target; 5 mg/kg, max 450 mg i.v. placebo
[21] 26 (18 completed) Parallel group 4-wk titration phase; 4-wk treatment phase; Up
to 4-wk tapering phase
Levorphanol 0.15 mg; Levorphanol 0.75 mg
[14] 127 (125 completed) Parallel group; Variable titration phase, mean 7 ds; Variable
treatment phase, mean 5 wk
Tramadol started 100 mg/d, titrated to max 400 mg/d, mean
275.5 mg/d; Placebo
[38] 18 with PHN (13
completed both arms)
Crossover 6-wk treatment 1-wk washout (adequacy verified);
6-wk treatment
Dextromethorphan started 120 mg/d, increased to max
960 mg/d, mean 439 mg/d; Placebo
[19] 22 (17 completed) Crossover 7-wk titration phase; 2-wk treatment phase; 2-wk
washout (no clear verification of adequacy;) Repeated three
times
Dextromethorphan titrated to max 960 mg/d, mean 400 mg/d;
Memantine titrated to max 58 mg/d, mean 35 mg/d; Loraze-
pam (active placebo) titrated to max 2 mg/d, mean 1.8 mg/d
[40] 24 (20 completed) Parallel group 1-wk titration phase 4-wk treatment phase Memantine started 10 mg/d titrated to 20 mg/d Placebo
[39] 27 PHN patients (26 PHN
patients completed)
Parallel group 14 d treatment phase GV196771 (antagonist at glycine binding site of NMDA recep-
tor) 300 mg/d Placebo
[50] 46 (40 completed
all four arms)
Crossover 3 4 single treatment session; Minimum 48-hr wash-
out period (no clear evidence of verification of adequacy of
washout period)
Clonidine 0.2 mg; Codeine 120 mg; Ibuprofen 800 mg; Placebo
[51] 11 (11 completed) Crossover 3 3 single treatment session; Minimum 24-hr wash-
out period (no clear evidence of verification of adequacy of
washout period)
Buspirone 20 mg m–chlorophenylpiperazine 40 mg; Placebo
[49] 21 (20 completed) Parallel group 12-wk treatment phase Acyclovir 800 mg/4 h while awake; Placebo
[41] 32 (29 completed) Parallel group 6-wk treatment phase Topical capsaicin 0.075% tds-qds; Placebo
[42] 143 (125 completed) Parallel group 6-wk treatment phase Topical capsaicin 0.075% qds; Placebo
[44] 23 (22 completed) Crossover 2-wk treatment phase 1-wk washout (verified by
similar pain intensities at start of each treatment period) 2-wk
treatment phase
Topical benzydamine 3%, up to six times daily; Placebo
[43] 22 (22 completed) Crossover 3 4 single treatment session; No washout Topical aspirin 1,000 mg/diethyl ether; Topical indomethacin
75 mg/diethyl ether; Topical diclofenac 100 mg/diethyl ether;
Placebo (lactulose/diethyl ether)
[45] 33 (32 completed) Crossover; Enriched enrolment; Time to exit variable; No
washout
Topical lidocaine patch 5% (700 mg); Placebo
[46] 40 (35 completed) Crossover; Single sessions; Min 72-hr washout (verified by .
75% of baseline pain intensity at start of each treatment period)
Topical lidocaine patch 5% (700 mg)—local and remotes sites;
Placebo vehicle and no patch
[47] 50 (39 completed
all sessions)
Crossover; Single session of 8 or 24 hr; Min 72-hr washout
(verified by . 75% of baseline pain intensity at start of each
treatment period)
Topical lidocaine gel 5%; Placebo
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amitriptyline against maprotiline and therefore could not be
included in the meta-analysis, but analysis of the data
revealed that amitriptyline was associated with efﬁcacy
(50% pain reduction) in 47% (15/32) of patients and
maprotiline in 38% (12/32); there was no signiﬁcant differ-
ence between the treatments [31].
There were two trials where no dichotomous data were
available. In one study, amitriptyline and nortriptyline were
equally effective, with approximately 50% achieving a ‘‘good’’
response (top two values on ﬁve-point scale) [30]. A parallel
design trial, with small numbers of patients in each arm,
compared amitriptyline, ﬂuphenazine, and a combination of
the two to placebo [35]. Amitriptyline showed signiﬁcant
beneﬁt; however, the addition of ﬂuphenazine made no
signiﬁcant improvement. Fluphenazine alone was no better
than placebo.
Efficacy of Gabapentinoids
Two parallel group trials that examined the efﬁcacy of
gabapentin in PHN were included in the meta-analysis
(559 patient episodes) [11,15]. In both trials, the dose of
gabapentin was titrated over 1–2 wk. In one study, the target
dose was 3,600 mg/d, a minimum of 1,200 mg/d was accept-
able, and 65% achieved the target dose, while 83% received at
least 2,400 mg/d [15]. The other trial compared the efﬁcacy of
two ﬁxed doses of gabapentin, 1,800 mg/d and 2,400 mg/d [11].
Unlike the previous study, patients unable to attain the target
doses were counted as withdrawals. Both doses showed
efﬁcacy with no signiﬁcant difference between the two. The
pooled results for gabapentin gave a NNT (50% pain
reduction) of 4.39 (3.34–6.07) (Table 3).
We located two parallel group placebo-controlled trials in
which the analgesic efﬁcacy of pregabalin was investigated
(411 patient episodes) [13,20], both trials revealing a
superiority over placebo. In one trial, a pregabalin dose of
either 300 or 600 mg/d, depending on creatinine clearance,
was administered as an attempt to obtain a predicted
pregabalin plasma concentration in all patients [13]. The
pooled NTT for a 50% pain reduction with pregabalin was
4.93 (3.66–7.58) (Table 3).
Efficacy of Opioids
We identiﬁed three RCTs that compared a conventional
opioid to placebo, two crossover studies that investigated
orally administered preparations [36], and one crossover trial
with intravenous (i.v.) morphine [37]. A parallel group trial
compared two doses of levorphanol [21]. Only the two
crossover RCTs that examined orally administered medica-
tion had extractable dichotomous data (211 patient episodes),
both of which demonstrated efﬁcacy. Oxycodone, titrated up
to a maximum of 60 mg/d [36], and controlled-release
morphine (mean dose 91 mg/d) (or methadone [mean dose
15 mg/d] as a back-up medication if the morphine was not
tolerated) [18] were associated with greater pain relief than
placebo (Table 3). Pooled results for opioids yielded a NNT of
2.67 (2.07–3.77). The Raja et al. study also made a direct
comparison of morphine/methadone to tricyclic antidepres-
sants; the NNT for antidepressants was 3.73 (2.43–7.99) and
for morphine/methadone 2.79 (2.01–4.6) [18].
In one non-placebo controlled parallel group study, two
doses of levorphanol were compared [21]. Of the 26 PHN
patients who entered the study, those treated with the 0.15-
mg dose of levorphanol achieved a 14% reduction in baseline
pain intensity, while the 0.75-mg dose was associated with a
33% reduction. When data from the 18 PHN patients who
completed the study were analysed, this reduction was 10%
and 42%, for the low- and high-dose groups, respectively.
The RCT that investigated i.v. morphine (0.3 mg/kg over 1
h, average dose 19.2 mg) assessed pain relief for 120 min, and
morphine treatment was associated with a signiﬁcant
improvement in pain relief, with a VAS score of 44.9 6 35.6
for morphine compared to 22.2 6 32.8 for placebo [37].
We identiﬁed a single placebo-controlled parallel group
RCT (108 patient episodes) that demonstrated the efﬁcacy of
orally administered controlled release tramadol (average
titrated dose 275.5 mg/d), which yielded an NNT of 4.76
(2.61–26.97) [14] (Table 3). The wide 95% CI indicates that
replication of this study is required before efﬁcacy can be
ﬁrmly stated.
Efficacy of Drugs Acting at N-Methyl-D-Aspartate (NMDA)
Glutamate Receptors
We were able to extract dichotomous data from three RCTs
(131 patient episodes) that compared NMDA receptor
antagonists to placebo, none of which demonstrated a
superior efﬁcacy over placebo (Table 3). Two studies were of
a crossover design: one compared dextromethorphan to
placebo (using benztropine as an active placebo) [38], and
Table 2. Continued
Reference Participants
Recruited (Completed)
Design and Duration of Intervention(s) Intervention
[48] 24 (24 completed) Crossover 3 3 single session; Min 1-wk washout (verified by si-
milar baseline pain intensities at start of each treatment period)
i.v. lidocaine 1 mg/kg i.v. lidocaine 5 mg/kg i.v. placebo
[16] 277 (270 completed
two-y follow-up)
Parallel group 4 injections at weekly intervals Intrathecal Lidocaine 3% 3 ml; Intrathecal Methylprednisolone
60 mg þ Lidocaine 3% 3 ml; Placebo (no lumbar puncture)
[17] 29 (25 completed followed
up to 24 wk)
Parallel group 4 injections at weekly intervals Intrathecal lidocaine 2% 3 ml þ methylprednisolone acetate
60 mg. Epidural lidocaine 2% 5 mlþ methylprednisolone 60 mg
[53] 62 (46 completed) Parallel group 6–8-wk treatment Auricular acupuncture. Placebo (‘‘Mock’’ TENS)
[54] 25 (22 completed) Parallel group 11 injections over 27 ds; Assessed 8 wk Subcutaneous Cronassial (gangliosides bovine brain tissue)
100 mg per injection; Placebo
[52] 20 (19 completed) Parallel group 4-wk treatment phase; Assessed d 20 and d 90 Vincristine 0.01% 20 ml Placebo Iontophoresis over 1 h
(20 treatments)
DOI: 10.1371/journal.pmed.0020164.t002
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Table 3. Summary of Data from Placebo-Controlled Trials for Which Dichotomous Data for Efficacy Could Be Extracted
Reference Active
Treatment
Number of Patient
Episodes
Benefit Efficacy
on Active
Efficacy
on Placebo
RB
(95% CI)
NNT (95% CI) Galbraith
Analysisb
TRICYCLIC
ANTIDEPRESSANTS
[32] amitriptyline 48 16/24 1/24 16 1.6
(2.3–111.28) (1.21–2.38)
[33] amitriptyline 59 15/34 5/25 2.21 4.15
(0.93–5.28) (2.13–81.64)
[34] desipramine 38 12/19 2/19 6 1.9
(1.55–23.26) (1.28–3.72)
[19] nortriptyline or 103 17/52 3/51 5.56 3.73
desipramine (1.73–17.83) (2.43–7.99)
Combined tricyclic
antidepressants
248 60/129 11/119 4.07 2.64
(2.25–7.34) (2.1–3.54)
p-value p , 0.0001 p , 0.001
Heterogeneity p-value 0.220 0.015
GABAPENTIN
[15] gabapentin 1,800–
3,600 mg
225
(229 randomised)
47/109 14/116 3.56 3.22
(2.09–6.1) (2.38–5)
[11] gabapentin 1,800 mg 226 37/115 16/111 2.23 5.63
(1.32–3.77) (3.51–14.29)
[11] gabapentin 2,400 mg 219 37/108 16/111 2.38 5.04
(1.41–4.02) (3.23–11.4)
Combined gabapentin 559a 121/332 30/227 2.65 4.39
(1.9–3.6) (3.34–6.07)
p-value p , 0.0001 p , 0.001
Heterogeneity p-value 0.41 0.19
PREGABALIN
[13] pregabalin 173 44/89 17/84 2.44 3.42
(1.52–3.92) (2.34–6.36)
[20] pregabalin 150 mg 162 21/81 8/81 2.63 6.23
(1.24–5.59) (3.62–22.2)
[20] pregabalin 300 mg 157 21/76 8/81 2.8 5.63
(1.32–5.94) (3.36–17.3)
Combined pregabalin 411a 90/246 33/246 2.56 4.93
(1.8–3.64) (3.66–7.58)
p-value p , 0.0001 p , 0.0001
Heterogeneity p-value 0.95 0.31
OPIOIDS
[38] oxycodone 100 29/50 9/50 3.22 2.5
(1.7–6.09) (1.74–4.41)
[18] morphine controlled 111 25/60 3/51 7.08 2.79
release or methadone (2.27–22.09) (2.01–4.6)
Combined opioids 211 54/110 12/101 3.89 2.67
(2.23–6.77) (2.07–3.77)
p-value p , 0.0001 p , 0.0001
Heterogeneity p-value 0.24 0.71
TRAMADOL
[14] tramadol 108 41/53 31/55 1.37 4.76
(1.04–1.8) (2.61–26.97)
NMDA RECEPTOR
ANTAGONISTS
[38] dextromethorphan 36 5/18 3/18 1.67 9
(0.47–5.97) NNTH 6.33 to : to NNTB 2.63
[19] dextromethorphan 34 5/17 2/17 2.5 5.67
(0.56–11.16) NNTH 11.27 to : to NNTB 2.26
[19] memantine 34 2/17 2/17 1 ‘
(0.16–6.3)
[39] GV196771 27 1/13 2/14 0.54 –15.17
(0.06–5.27) (NNTH 3.34 to : to NNTB 5.96)
Combined NMDA
receptor antagonists
131 13/65 9/66 1.48 23.86
(0.66–3.3) (NNTH 12.55 to : to NNTB 6.12)
p-value 0.34 0.5
Heterogeneity p-value 0.7 0.53
TOPICAL CAPSAICIN
[41] capsaicin 0.075% 32 8/16 1/16 8 2.29
(1.13–56.8) (1.4–6.05)
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the other had three treatment arms using dextromethorphan,
memantine, and lorazepam (as an active placebo) [19]. The
third study was of a parallel group design in which GV196771
(300 mg/d), an antagonist at the glycine binding site of NMDA
receptor, was found to have no superiority over placebo when
the data for the primary or secondary pain outcomesmeasures
were analysed, although it did have a reducing effect on the
area of static and dynamic mechanical allodynia [39].
In one further parallel group study, memantine (20 mg/d)
was shown not to be superior to placebo, although we were
unable to extract dichotomous outcome data from this study
[40].
Efficacy of Topically Administered Treatments
Two parallel group studies (175 patient episodes) com-
pared capsaicin cream (0.075% cream tds-qds) to placebo,
analysis of which yielded a pooled NNT of 3.26 (2.26–5.85)
(Table 3) [41,42]. The problems of maintaining adequate
Table 3. Continued
Reference Active
Treatment
Number of Patient
Episodes
Benefit Efficacy
on Active
Efficacy
on Placebo
RB
(95% CI)
NNT (95% CI) Galbraith
Analysisb
[42] capsaicin 0.075% 143 42/74 21/69 1.86 3.8
(1.24–2.8) (2.38–9.38)
Combined capsaicin 175 50/90 22/85 1.98 3.26
(1.33 2.95) (2.26 5.85)
p-value p , 0.008 p , 0.0001
Heterogeneity p-value 0.15 0.28
TOPICAL NSAIDs
[43] aspirin/diethyl
ether
44 18/22 6/22 3 1.83 high
(1.47–6.1) (1.26–3.34)
[43] indomethacin/
diethyl ether
44 10/22 6/22 1.67 5.5
(0.73–3.8) NNTH 10.3 to: to NNTB 2.17
[43] diclofenac/
diethyl ether
44 6/22 6/22 1 ‘
(0.38–2.63) NNTH 3.8 to : to NNTB 3.8
[44] benzydamine 46 14/23 15/23 0.93 –23
(0.6–1.45) NNTH 3.1 to : to NNTB 4.25
Combined NSAIDs 178 No data
(failed
heterogeneity
analysis)
p-value
Heterogeneity p-value 0.042 0.0053
TOPICAL LIDOCAINE p , 0.1
[45] lidoderm patch 64 29/32 13/32 2.23 2
(1.45–3.44) (1.43–3.31)
LIDOCAINE i.v.
[48] lidocaine 1 mg/kg 48 12/24 12/24 1 ;
(0.57–1.76)
[48] lidocaine 5 mg/kg 48 10/24 12/24 0.83 -12
INTRATHECAL THERAPIES
[16] lidocaine 181 6/91 3/90 1.98 10.7
(0.51–7.68) NNTH 32.7 to: to NNTB 10.45
[16] lidocaine and
methylpredni-
solone
179 82/89 3/90 27.64 1.13
(9–84.23) (1.05–1.22)
OTHER ORAL THERAPIES
[33] lorazepam 65 7/40 5/25 0.88 -40
(0.31–2.47) NNTH 4.52 to: to NNTB 5.85
[49] acyclovir 21 4/10 4/11 1.1 27.5
(0.37–3.27) NNTH 2.6 to: to NNTB 2.2
OTHER THERAPIES
[53] acupuncture 62 7/30 7/32 1.07 68.6
(0.43–2.69) NNTH 5.16 to : to NNTB 4.5
[52] vincristine
ionotophoresis
20 4/11 5/9 0.65 -5.21
(0.24–1.73) NNTH 1.6 to : to NNTB 4.17
a Single placebo group used to compare two doses.
b Some trials addressing a particular question will show treatment benefits that are clearly greater or less than the typical benefit observed in all the other trials addressing that question. In this case, there is heterogeneity between the trial
outcomes (i.e., trials with a RR that differs from the overall RR more than would be expected by chance). The method proposed by Galbraith was used to identify such atypical trials [28]. If the treatment benefit is greater, we have described
such trials as ‘‘high’’; if it is less, we have described them as ‘‘low.’’
DOI: 10.1371/journal.pmed.0020164.t003
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blinding to treatment in capsaicin studies, because of the
sensations that this treatment evokes on application, are well
documented. However, the choice of a parallel group design
does somewhat mitigate against this deﬁciency.
Dichotomous data were extracted from two RCTs (178
patient episodes) that compared topical anti-inﬂammatory
preparations to placebo. A crossover trial assessed single
doses of aspirin (median dose 1,000 mg), indomethacin
(median dose 75 mg), and diclofenac (median dose 100 mg)
in diethyl-ether against placebo [43]. The aspirin and
indomethacin preparations were associated with pain relief,
while the diclofenac preparation was not (Table 3). However,
signiﬁcant heterogeneity was detected in these studies, and
combined data could not be extracted.
A crossover trial of benzydamine 3% cream found no
signiﬁcant differences between active and placebo treatments
(Table 3) [44].
Three RCTs (123 participants recruited) of topical lido-
caine were identiﬁed; however, only one (64 patient episodes)
had extractable dichotomous data for efﬁcacy estimates
(Table 3): An enriched enrolment crossover trial that
included only participants who had reported moderate or
greater pain relief from lidocaine patches in an open label
study, compared lidocaine patch (5% lidocaine, 700 mg/
patch, up to 3 patches/d) to placebo [45]. The primary
outcome measure was ‘‘time to exit’’ from treatment;
however, a secondary measure (highest level of pain relief
sustained over at least 5 d) allowed an NNT of 2.00 (1.43–3.31)
to be calculated (Table 3). In another study, lidocaine 5%
patches were compared to two placebos (vehicle and ‘‘no
patch’’) in a single 12-h session; the authors reported that the
lidocaine patch was associated with higher pain-relief scores
compared to either placebo treatment [46]. In another RCT,
5% lidocaine gel was applied to painful areas of skin for
single sessions of 24 h under an occlusive dressing or 8 h with
no dressing [47]. The efﬁcacy of lidocaine gel was compared
to both vehicle placebo and application of lidocaine gel to a
site remote from the area of PHN, while locally applied
lidocaine gel was associated with analgesia efﬁcacy compared
to placebo. There was no signiﬁcant difference between
placebo and remote site treatments.
Efficacy of i.v. Lidocaine
Although not practical for long-term therapy of PHN,
treatment with i.v. lidocaine has been tested in two RCTs, and
we were able to extract dichotomous outcome data from one
of these: Neither lidocaine 1 mg/kg (48 patient episodes) nor 5
mg/kg (48 patient episodes), infused over 2 h were associated
with superior pain relief than saline infusion in a crossover
study (Table 3) [48]. The second trial was also of a crossover
design and compared placebo, morphine 0.3 mg/kg, and
lidocaine 5 mg/kg infused for 1 h (average total dose of
lidocaine 316 mg) and revealed no signiﬁcant difference
between lidocaine and placebo [37].
Efficacy of Intrathecally (i.t.) and Epidurally Administered
Drugs
A parallel group study (total of 270 patient episodes) was
identiﬁed that compared 3% lidocaine (3 ml, i.t.) (91 patient
episodes), 3% lidocaine (3 ml, i.t.), plus 60 mg methylpredni-
solone (i.t.) (89 patient episodes) and no treatment (90 patient
episodes) [16]. Intrathecal injections were carried out weekly
for 4 wk and patients followed up for 2 y. Analysis of
extracted dichotomous data revealed efﬁcacy associated with
the lidocaine/methylprednisolone treatment (NNT 1.13 [1.05–
1.22]), but not with i.t. lidocaine alone (Table 3).
Another parallel group study (25 patient episodes) that
compared a mixture of lidocaine 2% (3 ml) plus 60 mg of
methylprednisolone administered i.t. with lidocaine 2% (5
ml) plus 60 mg of methylprednisolone administered epidur-
ally was identiﬁed [17]. The lack of a placebo group dictated
that this study could not be included in the meta-analysis, but
the data revealed that the intrathecal treatment was
associated with efﬁcacy (50% pain reduction) in 92% (12/
13) of patients whilst efﬁcacy was seen in 17% (2/12) of
patients who received the epidural treatment. If the epidural
treatment is assumed to be a placebo, an NNT for the
intrathecal therapy could be calculated at 1.32 (0.99–2.00).
Efficacy of Miscellaneous Treatments
Two RCTs examined the benzodiazepine lorazepam: in one
crossover study (65 patient episodes), lorazepam (0.5–6 mg/d)
was not shown to be superior to placebo (Table 3) [33].
Lorazepam was also used as an active placebo in a crossover
study (34 patient episodes) in which two NMDA receptor
antagonists and lorazepam (mean dose 1.8 mg/d) were
compared; no signiﬁcant pain relief was reported between
the groups (Table 3) [19].
We were able to extract dichotomous data from a parallel
group study (21 patient episodes) that compared acyclovir
(800 mg/4 h for 12 wk) to placebo, in which no beneﬁt was
attributable to acyclovir (Table 3) [49].
We were unable to extract dichotomous efﬁcacy data from
a further two crossover studies: one multi-arm study (160
patient episodes) compared single doses of codeine 120 mg,
ibuprofen 800 mg, clonidine 0.2 mg to placebo, and there was
no signiﬁcant difference between treatments, but clonidine
had some efﬁcacy when compared to placebo [50]. In the
second trial (33 patient episodes), the 5HT1 agonists
buspirone and M-chloropiperazine were found to have no
beneﬁt when compared to placebo [51].
Transdermal iontophoresis of 0.01% (20 ml) vincristine
showed no beneﬁt for pain relief in a parallel group study (20
patient episodes) [52].
We were able to extract dichotomous data from one
parallel group study (62 patient episodes) that compared
auricular or body acupuncture to ‘‘mock TENS’’ as placebo;
no analgesic beneﬁt was associated with acupuncture (Table
3) [53].
We were unable to extract dichotomous outcome data for
efﬁcacy from a parallel group RCT (25 participants recruited,
22 completed) that compared subcutaneous injection of a
mixture of bovine gangliosides (Cronassial) to placebo; no
superiority over placebo was demonstrated [54].
Adverse Events
Of the trials from which we were able to extract
dichotomous data for efﬁcacy, we were able to extract
dichotomous data for minor and major harm from 18 and
20 reports, respectively (Tables 4 and 5).
For tricyclic antidepressants, the pooled analysis revealed
that 84% of participants reported minor adverse events
(NNH 5.67 [3.34—18.58]) (Table 4). In addition to dizziness
and sedation, the most frequently reported were anticholi-
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nergic in nature (dry mouth, constipation). However, the
incidence of these varied between studies (e.g., 13–74%
incidence of dry mouth) [18,34]. Three trials noted that
adverse events were more frequent during the titration phase
and then reduced during the maintenance phase [18,34].
Major adverse events: withdrawals were relatively small in
number and again related mostly to sedation and other
anticholinergic effects, one patient treated with desipramine
developed left bundle branch block, and one treated with
amitriptyline erythema multiforme [32,34]. The combined
NNH for major adverse events was 16.9 (8.85–178) (Table 5).
The pooled results for gabapentin gave a NNH of 4.07 (3.15–
5.74) for minor harm and 12.25 (7.69–30.2) for major harm
(Tables 4 and 5). The most frequently reported adverse events
were dizziness and somnolence. One death was reported in each
trial—both considered to be unrelated to study medication—one
in a gabapentin-treated patient and one in a placebo-treated
patient. Withdrawals in the ﬁrst pregabalin trial were mostly
related adverse events (28 out of 31 withdrawals in the active
treatment group), giving a NNH of 4.27 (2.78–9.18) and 4.86
(2.86–9.21) for minor and major harm, respectively (Tables 4 and
5) [13]. Compared to the gabapentin trials, the titration period
was more rapid, over 1 wk compared to 16 d and 4 wk. In the
second pregabalin trial, an 83% incidence of minor adverse
events was reported in the treatment group, but the incidence of
withdrawal was highest in the placebo group [20]. Since there was
signiﬁcant heterogeneity between the two studies, the NNH data
for pregabalin were not combined. The most frequent adverse
events associated with pregabalin were dizziness and somnolence.
For both oxycodone and controlled-release morphine,
constipation, nausea, and sedation were reported more often
in the study medication groups than with placebo [36]. It was
noted that nausea and sedation became less troublesome with
time, but not constipation. Compared to tricyclic antide-
pressants, morphine was associated with a higher incidence of
adverse events, in 72% compared to 36% of treated patients.
The incidence of withdrawals differed between trials, with no
signiﬁcant difference between oxycodone and placebo, but a
signiﬁcant difference between morphine or methadone and
placebo. The combined NNH for major harm was 6.29 (4.16–
12.8); due to the detection of signiﬁcant heterogeneity, we
were unable to calculate a combined NNH for minor harm,
but from one study [36], this was 3.57 (2.16–10.23) (Table 5).
For tramadol, the NNT for major harm was calculated at
10.81 (Table 5).
For NMDA receptor antagonists, dichotomous data were
available for minor adverse events from one trial 2.53 (1.38–
14.6) [39] and for major adverse events from two trials [38,39]
combined NNH 14.27 (NNTH of 4.8 to approximately NNTB
of 14.62).
No systemic adverse events were reported in the capsaicin
trials, but local irritation at the site of application of
capsaicin was the most frequently reported local adverse
event [41,42]. It was noted in both studies that these
symptoms decreased or disappeared during the course of
the trials. From the pooled data, a NNH for minor harm of
3.94 (2.5–8.6) was calculated (see Table 4). The most
frequently reported reason for withdrawal was burning pain
at the site of application. Dichotomous major adverse-events
data were only extractable from one RCT that yielded an
NNH of 4.67 (3.13–9.19) (Table 5) [42].
Lidocaine patches [45] were reported as being well
tolerated with no systemic adverse events and only minor
local skin reactions noted. There was no signiﬁcant difference
between lidocaine patch and placebo for minor adverse
events. There were only three withdrawals, two in the placebo
group associated with a skin reaction and worsening pain and
one in the lidocaine-treated group with severe depression.
For lidocaine and placebo gels, 38% of participants reported
local skin reactions and 19% reacted to the Tegaderm
dressing; there was no statistical difference between lidocaine
and placebo [47].
The topical anti-inﬂammatory treatments were well tol-
erated, with a low incidence of local skin irritation (see Table
4) [43,44].
Whilst we were unable to extract dichotomous adverse-
events data, no minor adverse effects were reported in either
epidural or intrathecal lidocaine and methylprednisolone
treated patients. Serial MRI scans were unchanged in all
groups, and seven patients failed to complete the 2-y follow-
up period, although no reasons were given for these
withdrawals [16]. One patient who under went epidural
injections had a cerebral haemorrhage 21 wk after injections,
thought to be unrelated to treatment [17].
Discussion
This systematic review of the literature suggests that there
is evidence of analgesic efﬁcacy (i.e., NNT , 5.00) in
established PHN for the following orally administered
therapies: tricyclic antidepressants, opioids, gabapentin,
tramadol, and pregabalin (Table 3). There is also evidence
that some topically administered therapies are associated
with analgesic efﬁcacy in appropriate patients: lidocaine
patch and capsaicin. Intrathecal administration of lidocaine
and methyl prednisolone is associated with long-lasting
analgesia. However, an important proviso must be made
when interpreting data derived using a meta-analytic
approach; the evidence supporting some therapies have been
derived from several studies, compromising a relatively large
number of patient episodes (e.g., tricyclic antidepressants,
gabapentinoids, and opioids), whereas others have been
derived from single studies (e.g., tramadol or intrathecal
methylprednisolone) and/or only a relatively low number of
patient episodes (e.g., topical lidocaine and capsaicin). The
data extracted from small and/or single unreplicated studies
needs to be viewed with a particular degree of caution (see
Tables 2 and 3).
Heterogeneity in clinical trial design and size is a frequent
Achilles’ heel of a meta-analytic approach. The European
Medicines Agency has recently published guidelines for
neuropathic pain studies, which hopefully, at least for
regulatory studies conducted in Europe, will dictate that
future trial methods will be more homogenous and, there-
fore, the data more comparable [55].
Some evidence supports the use of anticonvulsant (anti-
epileptic) drugs other than gabapentinoids in neuropathic
pain conditions other than PHN [10], but we could ﬁnd no
suitable trials that examined their use speciﬁcally in PHN.
Furthermore, we consider the classiﬁcation of drugs as
‘‘anticonvulsants’’ somewhat meaningless in this context,
since these drugs have disparate mechanisms of action.
Compliance of patients with treatment is an important
factor in the clinical effectiveness of therapies, and a major
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Table 4. Summary of Data from Placebo-Controlled Trials for Which Dichotomous Data for Minor Harm Could Be Extracted
Reference Minor Harm
Adverse Events Active Adverse Events on Placebo RR (95%CI) NNH (95%CI)
TRICYCLIC ANTIDEPRESSANTS
[32] 16/24 13/24 1.23 8
(0.771.96) NNTH 2.5 to : to NNTB 6.69
[33] 30/34 18/25 1.23 6.16
(0.941.62) NNTH 2.71 to : to NNTB 22.61
[34] 19/19 15/19 1.27 4.75
(1.011.6) (2.5436.68)
[19] No dichotomous data
Combined tricyclic antidepressants 65/77 46/68 1.25 5.67
(1.06 1.48) (3.34–18.58)
p-value p , 0.008 p , 0.005
Heterogeneity p-value 0.98 0.87
GABAPENTIN
[15] 62/113 32/116 1.99 3.67
(1.422.79) (2.536.66)
[11] 81/115 55/111 1.42 4.79
(1.141.77) (311.9)
[11] 81/108 55/11 1.51 3.93
(1.221.88) (2.647.66)
Combined gabapentin 224/336 87/227 1.55 4.07
(1.34–1.78) (3.15–5.74)
p-value p , 0.0001 p , 0.001
Heterogeneity p-value 0.25 0.76
PREGABALIN
[13] 77/89 53/84 1.37 4.27
(1.141.64) (2.789.18)
[20] No dichotomous data
OPIOIDS
[38] 38/50 24/50 1.58 3.57
(1.142.19) (2.1610.23)
[18] No dichotomous data
TRAMADOL
[14] 19/64 20/63 0.94 NNTB 48.58
(0.561.59) (NNTH 7.15 to : to NNTB 5.52)
NMDA RECEPTOR ANTAGONISTS
[38] 18/18 no data
[19] No dichotomous data
[39] 7/13 2/14 3.77 2.53
(0.95–14.96) (1.38 14.6)
Combined NMDA receptor antagonists 3.77 2.53
(0.95–14.96) (1.38 14.6)
p-value 0.06 0.03
Heterogeneity p-value
TOPICAL CAPSAICIN
[41] 5/16 2/16 2.5 5.33
(0.5711.05) NNTH 2.14 to : to NNTB 10.92
[42] 45/74 23/69 1.82 3.64
(1.242.66) (2.318.5)
Combined capsaicin 50/90 25/85 1.86 3.94
(1.3 2.71) (2.5 8.6)
p-value p , 0.001 p , 0.0003
Heterogeneity p-value 0.68 0.6
TOPICAL NSAIDs
[43] 0/22 0/22 1 ‘
(0.02 48.3) (NNTH 11.87 to : to NNTB 11.87
[43] 1/22 0/22 3 23
(0.13 69.8) NNTH 7.5 to : to NNTB 24
[43] 1/22 0/22 3 23
(0.13–69.8) NNTH 7.5 to : to NNTB 24
[44] 4/23 1/23 4 7.67
(0.4833.1) NNTH 3.27 to : to NNTB 22
Combined NSAIDs 2.95 30.2
(0.71–12.26) NNTH 11.2 to : to NNTB 43.6
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factor governing compliance is withdrawal due to side effects
(major harm). However, the dichotomous data for adverse
events that we have been able to extract must be viewed with
some caution for a number of reasons. Firstly, we were unable
to extract dichotomous adverse-events data for all studies
from which we were able to extract efﬁcacy data. Secondly,
the methods for collecting adverse-event data varied widely
between RCTs, with some trials actively seeking adverse-event
details with speciﬁc scoring systems, while others relied only
on patients volunteering such information. Thirdly, as with
the efﬁcacy data, many of the trials examined only short
treatment periods—sometimes only single sessions—and also
examined only a relatively small population of patients, a
combination of factors that seriously reduces the ability of
these RCTs to detect even relatively frequent adverse events.
We elected to use rates for total adverse events, as many
studies did not distinguish between events related or
unrelated to therapy; however, the use of total adverse events
as a measure could potentially yield a more global estimate of
the pattern of adverse events and remove a subjective
decision regarding such an association. Despite an appreci-
able frequency of minor adverse events, serious events were
rare; the few deaths that were reported were considered to be
unrelated to study medication (Tables 4 and 5).
Some data suggest that the following therapies are not
associated with efﬁcacy in PHN, within the dose range
examined: oral administration of certain NMDA receptor
antagonists (memantine, GV196771, and dextromethorphan),
codeine, ibuprofen, lorazepam, 5HT1 receptor agonists, and
acyclovir. Furthermore, topical administration of benzyd-
amine, diclofenac/diethyl ether, and vincristine (iontophore-
sis) are not efﬁcacious. Intrathecal administration of lidocaine
or epidural administration of lidocaine and methylpredniso-
lone are not associated with analgesia, nor is i.v. therapy with
lidocaine or subcutaneous injection of Cronassial. Acupunc-
ture is not associated with analgesic efﬁcacy in PHN. However,
it should be pointed out that, in contrast to the ‘‘positive’’
trials that contain large numbers of patient episodes, many of
the trials where an effect was not demonstrated represented
comparatively low numbers of patient episodes or were single-
dose studies, so it may be appropriate to regard such
interventions as ‘‘not yet adequately tested’’ rather than
demonstrating ‘‘no evidence of efﬁcacy.’’ Furthermore, the
potential confounds of variations in pharmacokinetics and
assessment of only a limited dose range/regimen dictate that a
‘‘lack of efﬁcacy’’ statement cannot be made with complete
conﬁdence for these interventions.
In 16 publications, cutaneous allodynia was measured
either qualitatively or quantitatively. Only bedside methods
were used for mechanical (15 papers) and thermal allodynia
(two papers). Quantitative data were presented from seven
studies; the rest were purely qualitative and usually accom-
panied by brief comments only. In general, improvement in
allodynia, or lack of it, paralleled changes in global pain
scores. Tricyclic antidepressants, oxycodone, i.v. and topical
lidocaine, and i.t. methylprednisolone reduced the intensity
and/or area of allodynia, whereas conventional NMDA
receptor antagonists did not, although there was an effect
on the area of dynamic and static mechanical allodynia
associated with the glycine site antagonist GV196771 [39]. No
useful data in this respect were available for gabapentin,
pregabalin, or tramadol.
The percentage of pain reduction or improvement that is
clinically meaningful, and can therefore be employed as a
dichotomous outcome measure, is controversial: the majority
of systematic reviews published to date have reported
dichotomous outcome data for efﬁcacy in terms of 50% pain
relief or reduction in baseline intensity. However, this
measure, as far as we are aware, has been validated for acute
pain only [56] and not for chronic neuropathic pain. Farrar et
al. have validated the use of a 30% reduction in pain intensity
as a clinically important dichotomous outcome measure for
chronic pain [57]. We therefore attempted to obtain such
30% dichotomous outcome data for comparative purposes
but were able to do so for only ﬁve studies; we have not
reported such data since we consider that this would not
Table 4. Continued
Reference Minor Harm
Adverse Events Active Adverse Events on Placebo RR (95%CI) NNH (95%CI)
p-value p , 0.14 p , 0.25
Heterogeneity p-value 0.94 0.6
TOPICAL LIDOCAINE
[45] 9/32 11/32 0.82 NNTB 16
(0.391.71) NNTH 6.07 to : to NNTB 3.46
LIDOCAINE i.v.
[48] 0/24 0/24 1 ‘
(0.02–48.45) NNTH 12.88 to : to NNTB 12.88
[48] 2/24 0/24 5 12.5
INTRATHECAL THERAPIES
[16] No adverse events reported
[16] No adverse events reported
OTHER ORAL THERAPIES
[33] 39/40 18/25 1.35 3.9
(1.051.73) (2.2913.8)
DOI: 10.1371/journal.pmed.0020164.t004
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Table 5. Summary of Data from Placebo-Controlled Trials for Which Dichotomous Data for Major Harm Could Be Extracted
Reference Major Harm
Withdrawals
on Active
Withdrawals
on Placebo
RR (95%CI) NNH (95%CI) Galbraith Analysisa
TRICYCLIC ANTIDEPRESSANTS
[32] 1/24 0/24 3 24
(0.13–70.1) NNTH 8.22 to : to NNTB 26.1
[33] 5/34 3/25 1.23 36.96
(0.32–4.67) NNTH 4.96 to : to NNTB 6.79
[34] 5/26 3/26 1.67 13
(0.44–6.28) NNTH 3.68 to : to NNTB 8.47
[19] 6/71 1/71 6 14.2
(0.74–48.5) (7.1–1708)
Combined tricyclic antidepressants 17/155 7/146 1.89 16.9
(0.83–4.32) (8.85–178)
p-value 0.13 0.03
Heterogeneity p-value 0.64 0.94
GABAPENTIN
[15] 21/113 14/116 1.54 15.35
(0.82–2.88) NNTH 6.32 to : to NNTB 35.78
[11] 15/115 7/111 2.07 4.84
(0.88–4.88) NNTH 6.95 to : to NNTB 110.27
[11] 19/108 7/111 2.79 8.86
(1.22–6.37) (5.06–35.7)
Combined gabapentin 55/336 21/227 1.95 12.25
(1.27–3) (7.69–30.2)
p-value p , 0.002 p , 0.001
Heterogeneity p-value 0.52 0.68
PREGABALIN
[13] 31/89 10/84 2.93 4.86 high
(1.53–5.6) (2.86–9.21)
[20] 150 mg 10/81 20/81 0.5 8.1 low
(0.25–1) NNTH 4.14 to : to NNTB 190
[20] 300 mg 16/76 20/81 0.85 27.48
(0.48–1.52) NNTH 10.53 to : to NNTB 5.96
Combined pregabalin 57/246 50/246 No data
(failed
heterogeneity
analysis)
p-value
Heterogeneity p-value p , 0.001 p , 0.001
OPIOIDS
[38] 6/50 5/50 1.2 50
(0.39–3.68) NNTH 7.02 to : to NNTB 9.76
[18] 20/71 1/71 20 3.74 high
(2.76–143) (2.66–6.27)
Combined opioids 26/121 6/121 2.37 6.29
(0.89–6.29) (4.16 12.8)
p-value p , 0.08
Heterogeneity p-value 0.015
TRAMADOL
[14] 11/ 64 5/ 63 2.17 10.81
(0.8–5.89) NNTH 4.84 to : to NNTB 36.4
NMDA RECEPTOR ANTAGONISTS
[38] 5/18 0/18 11 3.8
(0.65–185) (2.09–21.3)
[19] No dichotomous data
[19] No dichotomous data
[39] 0/13 1/14 0.36 –15.56
(0.02–8.12) (NNTH 8.62 to ; to NNTB 4.09)
Combined NMDA receptor antagonists 2.35 14.27
(0.29–19.08) (NNTH 4.8 to ; to NNTB 14.62)
p-value 0.42 0.32
Heterogeneity p-value 0.11 0.03
TOPICAL CAPSAICIN
[41] Three withdrawals,
unclear which arm from
[42] 18/74 2/69 8.39 4.67
(2.02–34.8) (3.13–9.19)
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reasonably reﬂect the breadth of included studies. However,
we suggest that in future, RCTs in PHN should report
responder rates for both 30% and 50% pain reduction,
although of course it could be argued that a debate
concerning the precise threshold for deﬁning a responder
is somewhat sterile, since it might be expected that the actual
ratio of placebo to active treatment responders might be
similar no matter which threshold was used, since the same
threshold would be applied to both interventions.
In many studies, evaluation of overall pain was measured
using the McGill Pain Questionnaire, but rarely were any
additional useful data presented. Triyclic antidepressants,
oxycodone, and i.t. methylprednisolone appeared to reduce
brief pain paroxysms as well.
Mood was assessed using validated tools (BDI, POMS,
HADS) in nine studies and quality of life (mainly SF36) in six.
Simple linear or categorical scales were used in ten studies for
sleep interference. In general, quality of life and sleep
changed in parallel with improved pain scores, whereas
changes in mood were inconsistent, the latter possibly due to
methodological differences.
Whilst the development of clinical management guidelines
for PHN, which are based upon high-quality evidence, is a
highly desirable goal, such guidelines can of necessity
include therapies only where evidence satisfying current
criteria exists. Justiﬁcation for a number of therapies in
current use by some practitioners is based upon clinical
experience and anecdote combined with research standards
of yesteryear, and therefore such therapies have not been
evaluated here. Unfortunately, since many of these therapies
are of little current commercial interest to the pharmaceut-
ical industry and do not fall within areas of interest of the
major research funding organisations, it is extremely
unlikely that an evidence base supporting or refuting such
therapies will ever be compiled. Other considerations also
inﬂuence evidence gathering relating to novel treatments:
where regulatory approval requires evidence of efﬁcacy and
safety compared with placebo, it may not be commercially
advantageous to undertake head-to-head studies directly
comparing efﬁcacy and safety against a current standard
treatment and thus such data are sparse. Furthermore, many
PHN patients take more than one therapy, and there is only
a very limited evidence base of the additive and synergistic
effects of combing therapies.
Nevertheless, from available evidence it is possible to
produce guidelines for management, but only with the caveat
that some therapies are excluded as they are not supported by
high-quality evidence. Lack of evidence may be because
adequate trials have shown no beneﬁt or because no adequate
trial has been undertaken.
A further problem arises from the fact that there is no
single pathophysiology that deﬁnes the generation and
persistence of PHN [3]. Future studies should use quantitative
sensory evaluation to clearly categorise subsets of patients
Table 5. Continued
Reference Major Harm
Withdrawals
on Active
Withdrawals
on Placebo
RR (95%CI) NNH (95%CI) Galbraith Analysisa
TOPICAL NSAIDs
[43] No withdrawals in any group
[43]
[43]
[44] 1/23 0/23 3 24
(0.13–70) NNTH 25.1 to : to NNTB 7.9
TOPICAL LIDOCAINE
[45] 0/32 2/32 0.2 NNTB 16.5
(0.01–4) NNTH 46.7 to : to NNTB 6.8
LIDOCAINE i.v.
[46]
[46] No withdrawals
INTRATHECAL THERAPIES
[16] Seven not complete 2-y
follow-up; groups unclear
[16] Four not complete 24-wk
follow-up;groups unclear
OTHER ORAL THERAPIES
[33] 6/40 3/25 1.25 33.3
(0.34–4.55) NNTH 5 to : to NNTB 7.21
[49] 2/21 3/21 0.7 NNTB 21
(0.12–3.6) NNTH 6.77 to : to NNTB 4.11
OTHER THERAPIES
[53] 13/30 3/32 6.93 1.8
(2.25–21.33) (1.27–3.08)
[52] 1/11 0/9 2.5 11
(0.11–54.8) NNTH 3.83 to : to NNTB 12.65
aSome trials addressing a particular question will show treatment benifits that are clearly greater or less than the typical benifit observed in all the other trials addressing that question. In this case there is heterogeneity between the trial
outcomes (i.e., trials with a RR that differs from the overall RR more that would be expected by chance). The method proposed by Galbraith was used to identify such atypical trials [28]. If the treatment benefit is greater, we have described
such trials as "high"; if it is less, we have described them as "low".
DOI: 10.1371/journal.pmed.0020164.t005
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contained within a study population and be powered to
permit separate evaluation of the data obtained for such
subsets.
It is important to include economic considerations in
development of a clinical management strategy, although it is
recognised that this will vary between health-care systems.
For example, where efﬁcacy and adverse events of two drugs
are similar, it would seem prudent to initiate treatment with
the less expensive drug. For example, a treatment plan for
oral therapy that proposes initial use of a tricyclic anti-
depressant, except where contra-indicated, might reserve the
use of the more expensive gabapentinoids for patients, where
the tricyclic antidepressant either fails to provide efﬁcacy
and/or is associated with unacceptable adverse events.
Similarly, the efﬁcacy of various opioids and tramadol
supports their use, but perhaps as a second-line therapy in
accordance with recommendations for the use of such drugs
in chronic non-cancer pain [58].
With the above provisos, and using the evidence evaluation
of this systematic review, the evidence base would support the
ﬁrst-line use of a tricyclic antidepressant for orally adminis-
tered treatment of PHN, reserving the gabapentinoids for
second-line use. However, a secondary proviso here might be
a consideration of the wisdom of using, as ﬁrst-line therapy, a
group of drugs that have regulatory approval in many
countries for the treatment of PHN (e.g., gabapentinoids)
against a group that generally do not (e.g., tricyclic
antidepressants). On the efﬁcacy evidence, ‘‘strong’’ opioids
could be considered as ﬁrst- or second-line therapy, although
the guidelines for use of opioids in non-malignant pain would
suggest that opioids might be sensibly reserved for use
following inadequate beneﬁt from tricyclic antidepressants
or gabapentinoids [58]. Logically, topical treatments might be
considered to have a lower potential for generating systemic
adverse effects than systemically administered therapies;
therefore, the early use of topical lidocaine or capsaicin
should be considered as a ﬁrst line, especially where
quantitative sensory evaluation (possibly supported by
measurement of epidermal neuronal density in a skin biopsy
[59]) has indicated that the patient falls into the ‘‘sensitised
nociceptor’’ as opposed to ‘‘deafferentation’’ sub-group of
PHN patients [3].
Intrathecal steroids appear to be associated with remark-
able beneﬁt in PHN patients [16], but this therapy may be
potentially hazardous [60–62], and this trial has not yet been
replicated. Therefore, we believe that a further high-quality
RCT of this therapy is desirable before recommendations can
be made regarding its use for PHN. This therapy is, of course,
not suitable for PHN within the cranial nerves innervation
territory.
There is little evidence regarding possible synergistic
effects of the various treatments to support or refute the
concomitant use of combinations of, e.g., tricyclic antide-
pressants, opioids, and gabapentinoids. However, it certainly
seems logical that concomitant use of drugs with different
mechanisms of action may offer additional beneﬁt to PHN
patients.
Although there is little direct evidence to support it, we
would like to make a ﬁnal recommendation that any
treatment plan should recognise the importance of the
biopsychosocial model of chronic pain and thus that any
pharmacologically based management of PHN should be
combined with advice on and management of psychological
and social aspects [63].
Acknowledgments
ASCR has been paid for providing services (e.g., consultancy advice,
lecture honoraria) and received travel expenses and entertainment
from several pharmaceutical companies with interest in this area,
e.g.: Pﬁzer, Boehringer-Ingelheim, GSK, Novartis, Vernalis, OHNO
Pharma, Ionix, UCB Pharma, Organon and Pierre Fabry. ASCR is a
member of the editorial board of PLoS Medicine.
TJN has received consultancy fees, honoraria, and travel expenses
from the following companies: GSK, Pﬁzer, Novartis, SchwarzPharma,
AstraZeneca, Ortho McNeil, Napp, Endo, and Renovis.
RWJ has received consultancy fees from Merck, Novartis, Menarini,
and Yamanouchi and travel grants from Novartis.
The authors recieved no funding for this study.
References
1. Cunningham AL, Dworkin RH (2000) The management of post-herpetic
neuralgia. Br Med J 321: 778–779.
2. Johnson RW (2001) Herpes zoster-predicting and minimizing the impact of
post-herpetic neuralgia. J Antimicrob Chemother 47: 1–8.
3. Fields HL, Rowbotham MC, Baron R (1998) Postherpetic neuralgia:
Irritable nociceptors and deafferentation. Neurobiol Dis 5: 209–227.
4. Bridges D, Thompson SWN, Rice ASC (2001) Mechanisms of neuropathic
pain. Br J Anaesth 87: 12–26.
5. Woolf CJ, Mannion RJ (1999) Neuropathic pain: Aetiology, symptoms,
mechanisms, and management. Lancet 353: 1959–1964.
6. Rowbotham MC, Petersen KL (2001) Zoster-associated pain and neural
dysfunction. Pain 93: 1–5.
7. Alper BS, Lewis PR (2002) Treatment of postherpetic neuralgia, a
systematic review of the literature. J Fam Pract 51: 121–128.
8. Collins S, Moore RA, McQuay HJ, Wiffen PJ (2000) Antidepressants and
anticonvulsants for diabetic neuropathy and postherpetic neuralgia: A
quantitative systematic review. J Pain Symptom Manage 20: 449–458.
9. Volmink J, Lancaster T, Gray S, Silagy C (1996) Treatments for postherpetic
neuralgia—A systematic review of randomized controlled trials. Fam Pract
13: 84–91.
10. Sindrup SH, Jensen TS (1999) Efﬁcacy of pharmacological treatments of
neuropathic pain: An update and effect related to mechanism of drug
action. Pain 83: 389–400.
11. Rice ASC, Maton S, Post Herpetic Neuralgia Study Group (2001)
Gabapentin in postherpetic neuralgia; a randomised, double-blind, con-
trolled study. Pain 94: 215–224.
12. Serpell MG, Neuropathic Pain Study Group (2002) Gabapentin in
neuropathic pain syndromes: A randomised, double-blind, placebo-
controlled trial. Pain 99: 557–566.
13. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, et al. (2003)
Pregabalin for the treatment of postherpetic neuralgia: A randomized,
placebo-controlled trial. Neurology 60: 1274–1283.
14. Boureau F, Legallicier P, Kabir-Ahmadi M (2003) Tramadol in post-
herpetic neuralgia: A randomized, double-blind, placebo-controlled trial.
Pain 104: 323–331.
15. Rowbotham MC, Harden N, Stacey B, Bernstein P, Magnus-Miller L (1998)
Gabapentin for treatment of postherpetic neuralgia. JAMA 280: 1837–1843.
16. Kotani N, Kushikata T, Hashimoto H, Kimura F, Muraoka M, et al. (2000)
Intrathecal methylprednisolone for intractable postherpetic neuralgia. N
Engl J Med 343: 1514–1519.
17. Kikuchi A, Kotani N, Sato T, Takamura K, Sakai I, et al. (1999) Comparative
therapeutic evaluation of intrathecal versus epidural methylprednisolone
for long-term analgesia in patients with intractable postherpetic neuralgia.
Reg Anesth Pain Med 24: 287–293.
18. Raja SN, Haythornwaite JA, Pappagallo M, Clark MR, Travison TG, et al.
(2002) Opioids versus antidepressants in postherpetic neuralgia. Neurology
59: 1015–1021.
19. Sang CN, Booher S, Gilron I, Parada S, Max MB (2002) Dextromethorphan
and memantine in painful diabetic neuropathy and postherpetic neuralgia:
Efﬁcacy and dose-response trials. Anesthesiology 96: 1053–1061.
20. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, et al. (2004)
Pregabalin reduces pain and improves sleep and mood disturbances in
patients with post-herpetic neuralgia: Results of a randomised, placebo-
controlled clinical trial. Pain 109: 26–35.
21. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, et al. (2003)
Oral opioid therapy for chronic peripheral and central neuropathic pain.
N Engl J Med 348: 1223–1232.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996)
Assessing the quality of reports of randomized clinical trials: Is blinding
necessary? Control Clin Trials 17: 1–12.
23. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, et al. (1996) A
systematic review of antidepressants in neuropathic pain. Pain 68: 217–227.
24. Moore RA, Tramer M, Carroll D, Wiffen PJ, McQuay HJ (1998) A
PLoS Medicine | www.plosmedicine.org July 2005 | Volume 2 | Issue 7 | e1640642
Analgesia in Postherpetic Neuralgia
quantitative systematic review of topically applied non-steroidal anti-
inﬂammatory drugs. Br Med J 316: 333–338.
25. Altman DG (1998) Conﬁdence intervals for the number needed to treat. Br
Med J 317: 1309–1312.
26. Fleiss JL (1981) Other measures of association: The odds ratio. Statistical
methods for rates and proportions, Chichester: John Wiley and Sons. p 64.
27. Armitage P, Berry G (1990) Statistical methods in medical research. Oxford:
Blackwell Scientiﬁc Publications, pp 194–196.
28. Galbraith RF (1988) A note on graphical presentation of estimated odds
ratios from several clinical trials. Stat Med 7: 889–894.
29. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. (1999) Improving
the quality of reports of meta-analyses of randomised controlled trials: The
QUOROM statement. Lancet 354: 1896–1900.
30. Watson CP, Vernich L, Chipman M, Reed K (1998) Nortriptyline versus
amitriptyline in postherpetic neuralgia: A randomized trial. Neurology 51:
1166–1171.
31. Watson CP, Chipman M, Reed K, Evans RJ, Birkett N (1992) Amitriptyline
versus maprotiline in postherpetic neuralgia: A randomized, double-blind,
crossover trial. Pain 48: 29–36.
32. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, et al. (1982)
Amitriptyline versus placebo in postherpetic neuralgia. Neurology 32: 671–
673.
33. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, et al. (1988)
Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurol-
ogy 38: 1427–1432.
34. Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B, et al.
(1990) Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther
47: 305–312.
35. Graff-Radford SB, Shaw LR, Naliboff BN (2000) Amitriptyline and
ﬂuphenazine in the treatment of postherpetic neuralgia. Clin J Pain 16:
188–192.
36. Watson CP, Babul N (1998) Efﬁcacy of oxycodone in neuropathic pain: A
randomized trial in postherpetic neuralgia. Neurology 50: 1837–1841.
37. Rowbotham MC, Reisner-Keller LA, Fields HL (1991) Both intravenous
lidocaine and morphine reduce the pain of postherpetic neuralgia.
Neurology 41: 1024–1028.
38. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB (1997) High-dose oral
dextromethorphan versus placebo in painful diabetic neuropathy and
postherpetic neuralgia. Neurology 48: 1212–1218.
39. Wallace MS, Rowbotham MC, Katz NP, Dworkin RH, Dotson RM, et al.
(2002) A randomized, double-blind, placebo-controlled trial of a glycine
antagonist in neuropathic pain. Neurology 59: 1694–1700.
40. Eisenberg E, Kleiser A, Dortort A, Haim T, Yarnitsky D (1998) The NMDA
(N-methyl-D-aspartate) receptor antagonist memantine in the treatment of
postherpetic neuralgia: A double-blind, placebo-controlled study. Eur
J Pain 2: 321–327.
41. Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE (1989) Topical
capsaicin treatment of chronic postherpetic neuralgia. J Am Acad
Dermatol 21: 265–270.
42. Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, et al. (1993) A
randomized vehicle-controlled trial of topical capsaicin in the treatment of
postherpetic neuralgia. Clin Ther 15: 510–526.
43. De Benedittis G, Lorenzetti A (1996) Topical aspirin/diethyl ether mixture
versus indomethacin and diclofenac/diethyl ether mixtures for acute
herpetic neuralgia and postherpetic neuralgia: A double-blind crossover
placebo-controlled study. Pain 65: 45–52.
44. McQuay HJ, Carroll D, Moxon A, Glynn CJ, Moore RA (1990) Benzydamine
cream for the treatment of post-herpetic neuralgia: Minimum duration of
treatment periods in a cross-over trial. Pain 40: 131–135.
45. Galer BS, Rowbotham MC, Perander J, Friedman E (1999) Topical lidocaine
patch relieves postherpetic neuralgia more effectively than a vehicle
topical patch: Results of an enriched enrollment study. Pain 80: 533–538.
46. Rowbotham MC, Davies PS, Verkempinck C, Galer BS (1996) Lidocaine
patch: Double-blind controlled study of a new method for post-herpetic
neuralgia. Pain 65: 39–44.
47. Rowbotham MC, Davies PS, Fields HL (1995) Topical lidocaine gel relieves
postherpetic neuralgia. Ann Neurol 37: 246–253.
48. Baranowski AP, De Courcey J, Bonello E (1999) A trial of intravenous
lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain
Symptom Manage 17: 429–433.
49. Surman OS, Flynn T, Schooley RT, Baer L, Parker S, et al. (1990) A double-
blind, placebo-controlled study of oral acyclovir in postherpetic neuralgia.
Psychosomatics 31: 287–292.
50. Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH (1988) Association
of pain relief with drug side effects in postherpetic neuralgia: A single-dose
study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther
43: 363–371.
51. Kishore-Kumar R, Schafer SC, Lawlor BA, Murphy DL, Max MB (1989)
Single doses of the serotonin agonists buspirone and m-chlorophenylpi-
perazine do not relieve neuropathic pain. Pain 37: 223–227.
52. Dowd NP, Day F, Timon D, Cunningham AJ, Brown L (1999) Iontophoretic
vincristine in the treatment of postherpetic neuralgia: A double-blind,
randomized, controlled trial. J Pain Symptom Manage 17: 175–180.
53. Lewith GT, Field J, Machin D (1983) Acupuncture compared with placebo
in post-herpetic pain. Pain 17: 361–368.
54. Staughton RC, Good J (1990) Double-blind, placebo-controlled clinical trial
of a mixture of gangliosides (‘Cronassial’) in post-herpetic neuralgia. Curr
Med Res Opin 12: 169–176.
55. Committee for Medicinal Products for Human Use (2004) Guideline on
clinical investigation of medicinal products intended for use in the
treatment of neuropathic pain. London: European Medicines Agency.
Report Number CHMP/EWP/252/03. Available: http://www.emea.eu.int/pdfs/
human/ewp/025203en.pdf. Accessed 26 May 2005.
56. McQuay HJ, Moore RA (1998) An evidence-based resource for pain relief.
Oxford: Oxford University Press. 264 p.
57. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM (2001) Clinical
importance of changes in chronic pain intensity measured on an 11-point
numerical pain rating scale. Pain 94: 149–158.
58. The British Pain Society (2004) Recommendations for the appropriate use
of opioids for persistent non-cancer pain. Available at: http://www.
britishpainsociety.org/pdf/opioids_doc_2004.pdf. Accessed: 8 June 2005.
59. Grifﬁn JW, McArthur JC, Polydefkis M (2001) Assessment of cutaneous
innervation by skin biopsies. Curr Opin Neurol 14: 655–659.
60. Nelson DA (1988) Dangers from methylprednisolone acetate therapy by
intraspinal injection. Arch Neurol 45: 804–806.
61. Nelson DA, Landau WM (2001) Intraspinal steroids: History, efﬁcacy,
accidentality and controversy with review of United States Food and Drug
Administration reports. J Neurol Neurosurg Psychiatry 70: 433–443.
62. Nelson DA, Landau WM, Lampe JB, Hindinger C, Reichmann H, et al.
(2001) Intrathecal methylprednisolone for postherpetic neuralgia. N Engl
J Med 344: 1019–1022.
63. Haythornthwaite JA, Benrud-Larson LM (2000) Psychological aspects of
neuropathic pain. Clin J Pain 16: S101–S105.
64. Tajti J, Szok D, Vecsi L (1999) Topical acetylsalicylic acid versus lidocaine
for postherpetic neuralgia; results of a double blind comparative trial.
Neurobiology 7: 103–108.
65. Bowsher D, Gill H (1991) Aspirin in chloroform lotion for topical pain
relief in postherpetic neuralgia: A double blind trial. J Pain 9: 16–17.
66. Devers A, Galer BS (2000) Topical lidocaine patch relieves a variety of
neuropathic pain conditions; an open label study. Clin J Pain 16: 205–208.
67. Coniam SW, Hunton J (1988) Benzydamine cream in post-herpetic
neuralgia. Anaesthesia 43: 901.
68. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, et al. (2003) Efﬁcacy of
lidocaine patch 5% in the treatment of focal peripheral neuropathic pain
syndromes: A randomized, double-blind, placebo-controlled study. Pain
106: 151–158.
69. Acosta EP, Balfour HH Jr (2001) Acyclovir for treatment of postherpetic
neuralgia: Efﬁcacy and pharmacokinetics. Antimicrob Agents Chemother
45: 2771–2774.
70. Killian JM, Fromm GH (1968) Carbamazepine in the treatment of
neuralgia. Use of side effects. Arch Neurol 19: 129–136.
71. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H (1994) Relief of post-
herpetic neuralgia with the receptor antagonist ketamine: A double-blind,
cross-over comparison with morphine and placebo. Pain 58: 347–354.
72. Brill S, Sedgwick PM, Hamann W, di Vadi PP (2002) Efﬁcacy of intravenous
magnesium in neuropathic pain. Br J Anaesth 89: 711–714.
73. Stow PJ, Glynn CJ, Minor B (1989) EMLA cream in the treatment of post-
herpetic neuralgia. Efﬁcacy and pharmacokinetic proﬁle. Pain 39: 301–305.
74. King RB (1993) Topical aspirin in chloroform and the relief of pain due to
herpes zoster and postherpetic neuralgia. Arch Neurol 50: 1046–1053.
75. Abadair AR, Kraynack BJ, Mayda J, Gintautas J (1996) Postherpetic
neuralgia: Response to topical clonidine. Proc West Pharmacol Soc 39:
47–48.
76. Watson CPN, Evans RJ (1985) A comparative trial of amitriptyline and
zimelidine in post-herpetic neuralgia. Pain 23: 387–394.
77. Watson CP, Evans RJ, Watt VR (1988) Post-herpetic neuralgia and topical
capsaicin. Pain 33: 333–340.
78. Nathan PW (1978) Chlorprothixene (taractan) in post-herpetic neuralgia
and other severe chronic pains. Pain 5: 367–371.
79. Langohr HD, Stohr M, Petruch F (1982) An open and double-blind cross-
over study on the efﬁcacy of clomipramine (Anafranil) in patients with
painful mono- and polyneuropathies. Eur Neurol 21: 309–317.
80. Ikebe H, Miyagawa A, Mizutani A, Miyamoto M, Taniguchi K, et al. (1995)
The effect of iontophoresis with several calcium channel blockers for PHN
patients. Masui 44: 428–433.
81. Gobel H, Stadler T (1997) Treatment of post-herpes zoster pain with
tramadol. Results of an open pilot study versus clomipramine with or
without levomepromazine. Drugs 53: 34–39.
82. Watt JW, Wiles JR, Bowsher DR (1996) Epidural morphine for postherpetic
neuralgia. Anaesthesia 51: 647–651.
83. Gerson GR, Jones RB, Luscombe DK (1977) Studies on the concomitant use
of carbamazepine and clomipramine for the relief of post-herpetic
neuralgia. Postgrad Med J 53: 104–109.
84. De Benedittis G, Besana F, Lorenzetti A (1992) A new topical treatment for
acute herpetic neuralgia and post-herpetic neuralgia: The aspirin/diethyl
ether mixture. An open-label study plus a double-blind controlled clinical
trial. Pain 48: 383–390.
85. Layman PR, Argyras E, Glynn CJ (1986) Iontophoresis of vincristine versus
saline in post-herpetic neuralgia. A controlled trial. Pain 25: 165–170.
86. Catala E, Ferrandiz M, Aliaga L, Serra R, Castra MA, et al. (1994)
PLoS Medicine | www.plosmedicine.org July 2005 | Volume 2 | Issue 7 | e1640643
Analgesia in Postherpetic Neuralgia
Intravenous lidocaine compared with sympathetic blocks as treatment for
postherpetic neuralgia. A 1 year survey. The Pain Clinic 7: 205–210.
87. Tamakawa S, Tsujimoto J, Iharada A, Ogawa H (1999) Treatment of
postherpetic neuralgia by topical application of prostaglandin E1-vaseline
mixture—A single blind controlled clinical trial. Masui 48: 292–294.
88. Moriyama M, Kitamura A, Ikezaki H, Nakanishi K, Kim C, et al. (2004)
Systemic ATP infusion improves spontaneous pain and tactile allodynia,
but not tactile hypesthesia, in patients with postherpetic neuralgia. J
Anesth 18: 177–180.
89. Rutgers MJ, Van Romunde LKJ, Osman PO (1988) A small randomised
comparative trial of acupuncture versus transcutaneous electrical neuro-
stimulation in postherpetic neuralgia. The Pain Clinic 2: 87–89.
Patient Summary
Background Postherpetic neuralgia (PHN) is the pain that people
sometimes get after shingles. It can be severe. Although many
treatments have been tried for it, doctors do not agree on how to best
treat it.
What Did the Researchers Do? They looked systematically to find all
the trials that have investigated treatments for PHN. They assessed each
trial to see if it could provide useful results—e.g., if it was well designed,
clear that they were treating patients with PHN, and that clear results
could be taken from the trials. They also looked to see if the trials had
assessed the possibility that the treatments could cause harm.
They found that there were a wide range of treatments that had been
tried. The most reliable oral treatments were tricyclic anti-depressants,
morphine-like drugs (opioids), and gabapentin (and related drugs). Some
topical treatments also worked: e.g., a local anaesthetic lidocaine and a
cream made from the active ingredient of chilli peppers—capsaicin.
However, for many treatments there was not enough evidence to assess
if they worked.
What Do These Results Mean? This type of review is the most reliable
form of evidence that doctors have available to them in deciding on
treatment. Even so, the results are not conclusive. Future trials should be
designed rationally to fill in the gaps of knowledge about the possible
treatments for this disorder. In the meantime, however, there are some
drugs that seem to work relatively well, and, outside of a clinical trial,
these drugs should be used first.
Where Can I Get More Information? Medline Plus discusses shingles
and neuralgia more widely:
http://www.nlm.nih.gov/medlineplus/ency/article/000858.htm
The Neuropathy Trust has a Web site with patient information:
http://www.neurocentre.com
The Varicella Zoster Research Foundation Web site also has useful
information for patients:
http://www.vzvfoundation.org
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